Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
APVO 
Aptevo Therapeutics Inc (APVO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: APVO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $420
1 Year Target Price $420
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.71% | Avg. Invested days 11 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.93M USD | Price to earnings Ratio - | 1Y Target Price 420 |
Price to earnings Ratio - | 1Y Target Price 420 | ||
Volume (30-day avg) 1 | Beta 5.77 | 52 Weeks Range 1.32 - 381.10 | Updated Date 09/17/2025 |
52 Weeks Range 1.32 - 381.10 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2680.54 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -99.45% | Return on Equity (TTM) -437.34% |
Valuation
Trailing PE - | Forward PE 3.94 | Enterprise Value -269123 | Price to Sales(TTM) 1.61 |
Enterprise Value -269123 | Price to Sales(TTM) 1.61 | ||
Enterprise Value to Revenue 0.12 | Enterprise Value to EBITDA 0.39 | Shares Outstanding 3287920 | Shares Floating 3287885 |
Shares Outstanding 3287920 | Shares Floating 3287885 | ||
Percent Insiders - | Percent Institutions 0.47 |
Upturn AI SWOT
Aptevo Therapeutics Inc
Company Overview
History and Background
Aptevo Therapeutics Inc. was formed as a spin-off from Emergent BioSolutions in 2016. They focus on developing novel immunotherapies for cancer and autoimmune diseases.
Core Business Areas
- ADAPTIRu2122 Platform: Aptevo's core technology platform for generating novel bispecific and multi-specific antibody therapeutics. These antibodies are designed to engage the immune system to fight cancer or modulate immune responses in autoimmune disorders.
- Hematology: Development and commercialization of products for hematological indications. Currently focusing on APVO436 for Acute Myeloid Leukemia (AML).
- Oncology: Developing immuno-oncology therapies utilizing the ADAPTIR platform.
Leadership and Structure
Marvin White is the President and CEO. The company operates with a functional organizational structure, focusing on R&D, clinical development, and commercial operations.
Top Products and Market Share
Key Offerings
- APVO436 (AML): A novel, potentially best-in-class investigational bispecific antibody candidate for Acute Myeloid Leukemia (AML). Currently in clinical trials. No significant revenue yet. Competitors include established AML therapies and other bispecific antibody developers.
- ADAPTIRu2122 Platform: Technology platform for developing bispecific and multi-specific antibodies. Generates revenue through partnerships and collaborations. Competitors are other antibody engineering platforms and companies developing bispecific/multi-specific antibodies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing significant growth, particularly in the areas of immuno-oncology and targeted therapies. Bispecific antibodies are a rapidly growing segment.
Positioning
Aptevo is a biotechnology company focused on developing innovative immunotherapies. Their ADAPTIR platform provides a competitive advantage in generating novel antibody constructs.
Total Addressable Market (TAM)
The TAM for bispecific antibodies in oncology is estimated to reach billions of dollars. Aptevo is positioned to capture a share of this market through successful clinical development and commercialization of its pipeline candidates.
Upturn SWOT Analysis
Strengths
- Proprietary ADAPTIRu2122 platform
- Experienced management team
- Strong pipeline of preclinical and clinical assets
- Focus on high-growth therapeutic areas
Weaknesses
- Limited financial resources
- Dependence on partnerships and collaborations
- Clinical trial risks
- Relatively small company size
Opportunities
- Strategic partnerships with larger pharmaceutical companies
- Expansion of the ADAPTIR platform to new therapeutic areas
- Positive clinical trial results
- Acquisition by a larger company
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- JNJ
- BMY
- XOMA
Competitive Landscape
Aptevo faces intense competition from larger, more established pharmaceutical companies. Their ADAPTIR platform provides a technological advantage, but they need to secure funding and partnerships to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Aptevo's historical growth has been driven by the advancement of its pipeline and strategic partnerships.
Future Projections: Future growth is dependent on the success of APVO436 and other pipeline candidates, as well as the company's ability to secure additional partnerships.
Recent Initiatives: Focusing on the APVO436 clinical trial, expanding the ADAPTIR platform, and seeking strategic partnerships.
Summary
Aptevo Therapeutics is a small biotechnology company with a promising technology platform and pipeline, particularly APVO436. However, it faces financial constraints and intense competition. Successful clinical trial results and strategic partnerships are critical for its future growth. The company needs to carefully manage its resources and execute its strategy effectively to realize its potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Aptevo Therapeutics Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Industry Reports
- Company Press Releases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Market share data are estimates and may not reflect actual figures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aptevo Therapeutics Inc
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2016-07-20 | President, CEO & Director Mr. Marvin L. White | ||
Sector Healthcare | Industry Biotechnology | Full time employees 37 | Website https://aptevotherapeutics.com |
Full time employees 37 | Website https://aptevotherapeutics.com | ||
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.